

**Correlation of Outcome of Neo adjuvant Concurrent
Chemo radiotherapy with Clinico-epidemiological
characteristics in locally advanced rectal
cancer patients: retrospective study**

A Thesis

**Submitted in Partial Fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine**

By

Wafaa Abd Elmonem Elnemrawy

M.B., B.ch., Faculty of Medicine, Tanta University

Under the Supervision of

Prof. Dr. Hany Mohammed Abd Elaziz

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Prof. Dr. Ramy Refaat Youssef Ghali

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Dr. Nesreen Ahmed Mosalam

*Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2019**



سورة المؤمنون - آية ٢٩



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the **Most Beneficent and Merciful** who gave me the strength to accomplish this work,*

*My deepest gratitude to my supervisor, **Prof. Dr. Hany Mohammed Abd Elaziz**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine - Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great and deep appreciation and thanks to **Prof. Dr. Ramy Refaat Youssef Ghali**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine - Ain Shams University, for his meticulous supervision, and his patience in reviewing and correcting this work,*

*I must express my deepest thanks to my **Dr. Nesreen Ahmed Mosalam**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine - Ain Shams University, for guiding me throughout this work and for granting me much of her time. I greatly appreciate her efforts.*

Thanks a lot to all my professors and colleagues for their considerable care and support.

*Special thanks to my **Parents** and all my **Family** members for their continuous encouragement, enduring me and standing by me.*

Last but not least, I would also like to thank my colleagues, my patients and everyone helped me in this study.

*✍ **Wafaa Abd Elmonem Elnemrawy***

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	iv
Introduction	1
Aim of the Work.....	5
Review of Literature	
Epidemiology	6
Risk factors of Rectal Cancer	11
Treatment.....	37
Patients and Methods.....	57
Results.....	61
Discussion	94
Summary	109
Conclusion.....	112
References	113
Arabic Summary	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
ACBE	<i>Air contrast barium enema</i>
AJCC	<i>American joint committee on cancer</i>
APC	<i>Adenomatous polyposis coli</i>
APR	<i>Abdominoperineal resection</i>
ASCO	<i>The American society of clinical oncology</i>
ASR	<i>Age-standardized rate</i>
BPR	<i>Bleeding per rectum</i>
CA 19-9	<i>Cancer antigen 19-9</i>
CAPOX	<i>Capecitabine & Oxaloplatin</i>
cCR	<i>Complete clinical response</i>
CDC	<i>Centers for disease control</i>
CEA	<i>Carcinoembryonic antigen</i>
CI	<i>Confidence interval</i>
CRC	<i>Colorectal cancer</i>
CRM	<i>Circumferential margin</i>
CT	<i>Computed tomography</i>
DCBE	<i>Double contrast barium enema</i>
DFS	<i>Disease free survival</i>
dMMR	<i>Mismatch repair protein</i>
ECOG	<i>Eastern Cooperative Oncology Group</i>
ERUS	<i>Endo rectal ultra sound</i>
ESMO	<i>European society for medical oncology</i>
FAP	<i>Familial adenomatous polyposis</i>
FOBT	<i>Fecal occult blood test</i>
FOV	<i>Field of view</i>
H&E	<i>Hematoxylin and eosin</i>
HNPCC	<i>Hereditary nonpolyposis colorectal cancer</i>

IBD	<i>Inflammatory bowel disease</i>
IHC	<i>Immune histochemical</i>
IMRT	<i>Intensity modulated radiotherapy</i>
LAR	<i>Low anterior resection</i>
LARC	<i>Locally advanced rectal cancer</i>
LE	<i>Local excision</i>
LR	<i>Local recurrence</i>
LVI	<i>Lympho vascular invasion</i>
MRF	<i>Meso rectal fascia</i>
MRI	<i>Magnetic resonance imaging</i>
MSI	<i>Microsatellite instability</i>
NA	<i>Not applicable or not reached</i>
NACRT	<i>Neo adjvant concurrent chemo radiotherapy</i>
NCCN	<i>National comprehensive cancer network</i>
NCRP	<i>National cancer registry program</i>
NCRP	<i>National Population-Based Cancer Registry Program</i>
NOS	<i>Not otherwise</i>
NSAIDs	<i>Nonsteroidal ant inflammatory drugs.</i>
OS	<i>Overall survival</i>
pCR	<i>Pathological complete response</i>
PET	<i>Positron emission tomography</i>
PNI	<i>Peri neural invasion</i>
RSNA	<i>Radiological society of North America</i>
SEER	<i>Surveillance, epidemiology and end results</i>
TME	<i>Total mesorectal excision</i>
TME	<i>Total mesorectal excision</i>
UICC	<i>International union against cancer</i>
US	<i>United states</i>
VC	<i>Virtual colonoscopy</i>
VMAT	<i>Volumetric modulated arc therapy</i>

List of Tables

Table No.	Title	Page No.
Table (1):	Incidence rate/100,000 population of rectal cancer in Lower, Middle, Upper Egypt: males according to NCRP.	8
Table (2):	Incidence rate/100,000 population of rectal cancer in Lower, Middle, Upper Egypt: females according to NCRP.	9
Table (3):	Primary tumor (T) staging of primary rectal cancer.	32
Table (4):	Regional lymph nodes (N) staging of rectal cancer	33
Table (5):	Distant metastasis (M) staging of rectal cancer.	33
Table (6):	Anatomic stage/prognostic groups.....	34
Table (7):	Modified Ryan scheme for tumor regression score.....	35
Table (8):	Randomize studies of preoperative concurrent chemo radiotherapy for rectal c.	40
Table (9):	Randomize studies of preoperative short course radiotherapy (5Gy×5f) for rectal cancer.	41
Table (10):	(ESMO) guidelines recommended that the treatment for rectal cancer should be stratified based on the recurrence risk	43

Table (11):	Randomize studies of preoperative concurrent chemo radiotherapy with Oxaliplatin for rectal cancer.....	54
Table (12):	Patients demographic characteristics distribution of the study group.....	61
Table (13):	Disease factors distribution of the study group.....	63
Table (14):	Treatments factors distribution of the study group.....	65
Table (15):	Response after neoadjuvant CCRT distribution of the study group.....	66
Table (16):	Loco-regional recurrence distribution of the study group.	68
Table (17):	Time of distant Mets. Distribution of the study group.	69
Table (18):	Overall survival distribution of the study group.....	69
Table (19):	Median of loco-regional recurrence free survival of the study group.	70
Table (20):	Median of distant metastasis free survival of the study group.....	71
Table (21):	Median of disease free survival of the study group.....	71
Table (22):	Median of overall survival of the study group.....	72
Table (23):	Relation between patient's demographic characteristics and DFS.....	73
Table (24):	Relation between disease factors and DFS. ...	74

Table (25):	Relation between treatment factors and DFS.....	76
Table (26):	Relation between DFS and responses after neoadjuvant CCRT.....	78
Table (27):	Relation between patient's demographic characteristics and overall survival.....	80
Table (28):	Relation between disease factors and overall survival.....	81
Table (29):	Relation between treatment factors and overall survival.....	83
Table (30):	Relation between overall survival and responses after neoadjuvant CCRT.....	85
Table (31):	Multivariate analysis of independent predictors through overall survival in all patients.	89

List of Figures

Figure No.	Title	Page No.
Figure (1):	Globocan 2012 Egypt fact sheet: estimated cancer incidence in both sex.....	9
Figure (2):	Globocan 2012 Egypt fact sheet: estimated cancer incidence in both sex.....	10
Figure (3):	Algorithm for colorectal cancer screening.....	18
Figure (4):	Kaplan-Meier loco-regional recurrence of the study group.....	70
Figure (5):	Kaplan-Meier DFS of the study group.....	71
Figure (6):	Kaplan-Meier of OS of the study group.	72
Figure (7):	Kaplan-Meier DFS between grades in the study group.....	75
Figure (8):	Kaplan-Meier DFS between types of surgery in the study group.....	77
Figure (9):	Kaplan-Meier DFS between T staging in the study group.....	79
Figure (10):	Kaplan-Meier DFS between N staging in the study group.....	79
Figure (11):	Kaplan-Meier Overall survival between grades in the study group.	82
Figure (12):	Kaplan-Meier Overall survival between surgeries in the study group.	84
Figure (13):	Kaplan-Meier Overall survival between y Pathological Staging T in the study group.....	87

Figure (14): Kaplan-Meier Overall survival between y Pathological Staging N in the study group. ...	87
Figure (15): Kaplan-Meier Overall survival between y Pathological Staging LVI in the study group.....	88
Figure (16): Kaplan-Meier Overall survival between y Pathological Staging pathological responses in the study group.	88
Figure (17): Hazard ratio multivariate analysis of independent predictors through overall survival in all patients.	90

Abstract

Background: The treatment of (LARC) is subject to continuous change due to better diagnostic tools, radio therapeutic techniques and chemotherapeutic agents. It is clear, that a multimodality approach is the only way to achieve satisfactory local recurrence and survival rates in this type of cancer. Widespread use of neoadjuvant therapy have all contributed to decrease the rate of local recurrence, raise the quality of life and the probability of overall survival.

Aim of the Work: to correlate clinico-epidemiological factors of locally advanced rectal cancer patients with outcomes of neoadjuvant concurrent chemo radiotherapy (NACRT) regarding disease -free survival (DFS) and overall survival (OS).

Patients and Methods: In this retrospective study, data were collected from files of 100 patients with locally advanced rectal cancer patients with cT3-4 or any cT/cN+ disease assessed using colonoscopy, enhanced computed tomography, and or magnetic resonance imaging, between Jan 2010 and December 2016 in oncology department of Ain Shams faculty of medicine and Nasser institute of treatment and research. The patients received long course radiotherapy (45-50.4 Gy/1.8-2 Gy) combined with concurrent chemotherapy. Surgery was done after NACCRT, Which had been abdominoperineal resection (APR), low anterior resection (LAR), exploration. Data were collected retrospectively by reviewing of medical records (hard copy records, pre treatment radiology, radiotherapy documentation, surgical and pathology reports, and follow up clinic records). Ethics committee of Ain Shams faculty of medicine approved the study

Results: This study showed younger age presentation of our population with median age 44yr. The study showed that grades of rectal cancer having statistically difference with DFS and OS with P value 0.009 and hazard ratio 1.919 with 95% CI. Types of surgery (LAR, APR and exploration) had statistically significant difference and impact on DFS and OS with P value 0.044 and hazard ratio 1.646 with 95% CI. y-pathological nodal staging had statistically significant difference on DFS and OS with P value 0.042 and hazard ratio 1.633 with 95% CI. Pathological response that achieved after CCRT having statistically significant difference on DFS and OS with P value 0.048 and hazard ratio 1.323 with 95%CI. These parameters are independent prognostic factors and considered during management of patients with locally advanced rectal cancer.

Conclusion: assessment of LARC patients before selection type of therapy is very important to select whom patient will benefit from NACRT, will gain functional preservation at the time of surgery and increase probability of overall survival.

Key words: Neoadjuvant Concurrent Chemo radiotherapy, Clinico-epidemiological characteristics rectal cancer.

Introduction

Colorectal cancer is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2018, 43,030 new cases of rectal cancer are estimated in the United States (23, 110 cases in men; 16, 110 cases in women). During the same year, it is estimated that 50,630 people will die from rectal and colon cancer combined (*Siegel et al., 2018*).

It accounts for over 9% of all cancer incidence and accounts for about 8.5% of all cancer related mortality. Countries with the highest incidence rates include Australia, New Zealand, Canada and the United States. The countries with the lowest risk include China, India, and parts of Africa (*Tabaries et al., 2015*).

According to the results of the National Population-Based Registry Program of Egypt 2008-2011, these data showed that ASR of 6 and 4.9 per 100, 000 in men and women respectively. The incidence represents 3.2% of all cancers in both sexes. 1070rectal cancer cases suspected within 2020 (568 males and 505 females with male to female ratio (1.1:1) (*Amal et al., 2014*).

Modifiable risk factors associated with 30–50% of the colorectal cancer risk is attributable to lifestyle factors such

as smoking, high consumption of red and processed meat, obesity, diabetes, and excessive consumption of alcohol (*Kolligs et al., 2016*).

Screening for rectal cancer is effective in reducing the mortality risk among the screened population. In A cohort CRC screening feasibility study using fecal occult blood testing, showed a reduction in rectal cancer mortality in screened group compared to being unscreened (*Jan et al., 2014*).

Other screening tests, such as colonoscopy and sigmoidoscopy, have been proposed. According to a recent randomized trial in the United Kingdom, a one-time flexible sigmoidoscopy screening between 55 and 64 years of age reduced colorectal cancer incidence by 33% and mortality by 43% (*Atkin et al., 2010*).

The main manifestation of rectal cancer are melena, abdominal pain, unexplained iron deficiency anemia and/or a change in bowel habits with positive family history of colorectal cancer and polyps. Full colonoscopy and Pelvic MRI are required for all rectal cancer patients at time of diagnosis. For detection of distant metastasis, CT of the chest is required (*Kolligs et al., 2016*).

The treatment of locally advanced rectal cancer is subject to continuous change due to better diagnostic tools,

radio therapeutic techniques and chemotherapeutic agents. It is clear, that a multimodality approach is the only way to achieve satisfactory local recurrence and survival rates in this type of cancer (*Nordlinger et al., 2012*).

Locally advanced rectal cancer (LARC) has often developed postoperative local recurrence. Widespread use of neoadjuvant therapy have all contributed to decrease the rate of local recurrence, raise the quality of life and the probability of overall survival (*Joshua and Julio, 2015*).

In an effort to reduce further the incidence of margin positivity, local recurrence and improve survival of rectal cancer, preoperative neoadjuvant radiotherapy with or without chemotherapy has been introduced as adjuvant to total mesorectal excision (TME). A number of trials have reported reduced local recurrence rates and a potential survival advantage associated with preoperative radiotherapy (*Belluco et al., 2011*).

It also needs to judge and consider the balance between the higher recurrence rate and the higher sphincter-preserving rate. In addition, the evaluation of the efficacy of neoadjuvant radio chemotherapy should be as enough as possible. It needs to maximally improve the accuracy of evaluation (*Benson et al., 2015*).